Ethris
Latest round
- Debt
Last raised
- Sep 2026
Total raised
- $61M
Investors
- 3
About Ethris
Established in 2009 and based in Planegg, Germany, Ethris GmbH operates as a biotechnology company that provides transformative messenger RNA (mRNA) enable to develop discover, and design therapeutic antibodies. As of 2022, Carsten Rudolph is the CEO of Ethris. The company has developed a proprietary Stabilized Non-Immunogenic mRNA (SNIM® RNA) platform and uses its other proprietary technology platforms to generate protein replacement therapy candidates focusing on rare genetic disorders. Ethris is advancing a novel class of mRNA products for respiratory and infectious diseases as well as prophylactic vaccines. Thus, tackling influenza, COVID-19, and other seasonal respiratory viruses. Ethris' therapeutic programs include ETH47 – Influenza & SARS-CoV-2, ETH42 – Primary ciliary dyskinesia, and ETH45 – Pulmonary alveolar proteinosis. Additionally, its vaccine programs include mucosal vaccines, multivalent vaccines, mutation-agnostic vaccines, ETH49 – Hepatitis C, and ETH50 – Betacoronavirus.
Who invested in Ethris
3 investors across 3 rounds
See all investors in Ethris
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ethris
Who invested in Ethris?
Ethris has 3 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ethris raised?
Ethris has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Ethris last raise money?
Ethris's most recent round on record is a Debt, in Sep 2026.
What does Ethris do?
Established in 2009 and based in Planegg, Germany, Ethris GmbH operates as a biotechnology company that provides transformative messenger RNA (mRNA) enable to develop discover, and design therapeutic antibodies.
Where is Ethris headquartered?
Ethris is headquartered in Planegg, Germany.
Which VCs invest in companies like Ethris?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Ethris's stage. Their profiles are linked below.
VCs backing biotechnology startups at Debt
Raising like Ethris? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.